Matrix metalloproteinase-3 (MMP-3) (MMP-3)

Matrix metalloproteinase-3 (MMP-3), historically referred to as proteoglycanase or stromelysin-1, is a zinc-dependent endopeptidase that plays a fundamental role in the degradation and remodeling of the extracellular matrix. It is expressed by various cell types, including chondrocytes and synovial fibroblasts, and is capable of degrading a broad spectrum of substrates such as proteoglycans (particularly aggrecan), fibronectin, laminin, and several collagen types (III, IV, IX, and X). MMP-3 is particularly significant for its ability to activate other pro-MMPs, such as pro-MMP-1 and pro-MMP-9, thereby acting as a central regulator of the proteolytic cascade in connective tissues. In diseases such as osteoarthritis and rheumatoid arthritis, the pathological upregulation of MMP-3 leads to the progressive and irreversible destruction of articular cartilage. Historically, it was a primary target for broad-spectrum matrix metalloproteinase inhibitors, though many clinical trials were discontinued due to a lack of selectivity and the emergence of musculoskeletal side effects characterized by joint pain and stiffness. Modern clinical applications utilize MMP-3 levels in serum and synovial fluid as sensitive biomarkers for monitoring disease activity and joint destruction in inflammatory arthritis.

Other names

ProteoglycanaseStromelysin-1Neutral proteoglycanaseTransin-1MMP3Matrix metallopeptidase 3

Inhibition of zinc-dependent catalytic activity by binding to the active site and chelating the essential zinc ion, thereby preventing the cleavage of extracellular matrix substrates.